We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+36.38%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$569M
AUM Growth
+$154M
Cap. Flow
+$48.6M
Cap. Flow %
8.53%
Top 10 Hldgs %
94.85%
Holding
13
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ONCR
Oncorus, Inc.
ONCR
+$55M

Top Sells

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$6.45M

Sector Composition

Rank Sector Weight
1 Healthcare 95.3%
2 Miscellaneous 4.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCRR
1
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$104M 18.31%
3,370,982
– –
RPTX
2
DELISTED
Repare Therapeutics
RPTX
$81.9M 14.39%
2,388,337
– –
ITOS
3
DELISTED
iTeos Therapeutics
ITOS
$79.7M 13.99%
2,355,557
– –
ONCR
4
DELISTED
Oncorus, Inc.
ONCR
$76.8M 13.5%
+2,377,031
New +$55M
HARP
5
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$64.8M 11.37%
389,842
– –
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$37.6M 6.61%
308,686
– –
GTHX
7
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$25.6M 4.5%
1,423,794
– –
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$25.3M 4.45%
2,331,534
-523,203
-18% -$6.45M
ADCT icon
9
ADC Therapeutics
ADCT
$146M
$17.3M 3.03%
539,648
– –
YMAB
10
DELISTED
Y-mAbs Therapeutics
YMAB
$16.7M 2.93%
337,291
– –
MRUS
11
DELISTED
Merus
MRUS
$12.3M 2.16%
700,879
– –
AUTL
12
Autolus Therapeutics
AUTL
$623M
$355K 0.06%
39,740
– –

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2020 Portfolio in Review

As of Q4 2020, MPM BioImpact held 13 positions worth $569M, up 37% from $415M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

MPM BioImpact deployed $48.6M of net new capital in Q4 2020, opening 1 new position. Its largest new stake was Oncorus, Inc.: 2,377,031 shares worth $76.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Epizyme, Inc, an estimated $6.45M trimmed.

  • MPM BioImpact's largest Q4 2020 buy was Oncorus, Inc.: 2,377,031 shares worth $76.8M.
  • MPM BioImpact's biggest Q4 2020 reduction was Epizyme, Inc, cutting an estimated $6.45M.
  • MPM BioImpact's ten largest holdings make up 95% of its $569M portfolio in Q4 2020.
  • MPM BioImpact opened 1 new position and closed 0 in Q4 2020.
  • MPM BioImpact's portfolio value rose 37% quarter-over-quarter to $569M.

Based on MPM BioImpact's 13F filing for Q4 2020, filed 16 Feb 2021.